Taiho Oncology Announces Presentation of Data From a U.S. Real-Word Study of Oral Decitabine and Cedazuridine

Retrospective analysis of patients with myelodysplastic syndromes showed trends in treatment patterns that suggest: improved trend persistence with oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents beyond 6 months comparable persistence between oral decitabine and cedazuridine and intravenous/subcutaneous hypomethylating agents at early stages of therapy PRINCETON, N.J., Dec. 10, 2023 /PRNewswire/ — Taiho Oncology, Inc. announced […]

Related Keywords

Oakville ,Ontario ,Canada ,New Jersey ,United States ,Yale School ,Switzerland ,Canadian ,American ,Judy Kay Moore ,Us Cerner Enviza ,Tehseen Salimi ,Samer Zeidan ,Yale Cancer Center ,Otsuka Holdings Co Ltd ,National Cancer Institute ,American Society Of Hematology ,Taiho Pharmaceutical Co Ltd ,Leukemia Lymphoma Society ,End Results Program ,Linkedin ,Twitter ,Taiho Oncology Inc ,Yale School Of Medicine ,Taiho Oncology ,American Society ,Annual Meeting ,Associate Professor ,Interim Chief ,Hematologic Malignancies ,Smilow Cancer Hospital ,Senior Vice President Medical Affairs ,Oncology Contact ,Effective Antihypertensive ,Myelodysplastic Syndrome ,Research Funded ,End Results ,Clin Lymphoma Myeloma ,